J. Fridey

S. Glynn, J. Fridey, G. Schreiber, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation

A. Nademanee, J. Fridey, L. Weiss, 2007, Transfusion.

Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors

J. Fridey, R. Sposto, K. Ruccione, 2012, Pediatric blood & cancer.

Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study.

S. Glynn, J. Fridey, E. Murphy, 1999, Archives of internal medicine.

Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study

D. Smith, C. Nass, J. Fridey, 2003, Neurology.

Neurologic abnormalities in HTLV-I– and HTLV-II–infected individuals without overt myelopathy

J. Fridey, E. Murphy, J. Engstrom, 2009, Neurology.

Out-Of-Hospital Transfusion Therapy

J. Fridey, C. Kasprisin, L. Issitt, 1994 .

Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals.

D. Rosskopf, K. Jöckel, P. Forster, 1999, Journal of the American Society of Nephrology : JASN.

The impact of male‐to‐male sexual experience on risk profiles of blood donors

S. Glynn, C. Nass, J. Bethel, 2005, Transfusion.

Behavioral and infectious disease risks in young blood donors: implications for recruitment

S. Glynn, J. Bethel, J. Fridey, 2003, Transfusion.

HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors

J. Stevens, R. Khabbaz, J. Fridey, 1997, Neurology.

Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection.

A. E. Yeo, J. Fridey, E. Murphy, 2008, Blood.

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

J. Fridey, R. Strauss, D. Vesole, 2004, Blood.

Fetal cystic hygroma and Turner's syndrome.

D. A. Ritter, J. Fridey, P. Ming, 1986, American journal of diseases of children.

Probable transfusion transmission of West Nile virus from an apheresis platelet that screened non‐reactive by individual donor‐nucleic acid testing

J. Fridey, Robert E Snyder, S. Stramer, 2020, Transfusion.

Laboratory abnormalities in former blood donors seropositive for human T-lymphotropic virus types 1 and 2: a prospective analysis.

S. Glynn, J. Fridey, G. Schreiber, 2000, Archives of pathology & laboratory medicine.

Process for Pathogen Inactivation: The SPRINT Trial Therapeutic Efficacy and Safety of Platelets Treated with a Photochemical

J. Fridey, D. Vesole, R. Benjamin, 2012 .

Practical aspects of out-of-hospital transfusion.

J. Fridey, 1997, American Journal of Clinical Pathology.

Sepsis from an apheresis platelet contaminated with Acinetobacter calcoaceticus/baumannii complex bacteria and Staphylococcus saprophyticus after pathogen reduction

E. Crawford, J. Fridey, M. Busch, 2020, Transfusion.

A question of clarity: redesigning the American Association Of Blood Banks blood donor history questionnaire--a chronology and model for donor screening.

D. Kessler, J. Fridey, M. Townsend, 2007, Transfusion medicine reviews.

Demographic determinants of hepatitis C virus seroprevalence among blood donors.

A. Williams, C. Nass, J. Fridey, 1996, JAMA.

Neurologic abnormalities in HTLV-I– and HTLV-II–infected individuals without overt myelopathy

J. Fridey, E. Murphy, J. Engstrom, 2009, Neurology.